Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    Advancing Therapeutic Discovery for Select Resistant Gram-Negative Bacteria

    By Global Biodefense StaffApril 26, 2017
    Biosecurity Research Programs
    Image: HMS (iStock).
    Share
    Facebook LinkedIn Reddit Email

    In response to the threat presented by increasing numbers of infections caused by antimicrobial–resistant (AR) and multidrug-resistant (MDR) Gram-negative bacterial pathogens, the NIAID Division of Microbiology and Infectious Diseases (DMID) has established research programs to facilitate development of therapeutics targeting select pathogens.

    Under a new Funding Opportunity Announcement (FOA), NIAID DMID is inviting applications for milestone-driven research projects focused on development and utilization of novel predictive assays, models and/or research tools based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Enterobacteriaceae (CRE), MDR Acinetobacter and/or MDR Pseudomonas aeruginosa.

    The objective of this FOA is to support milestone-driven projects focused on developing and utilizing novel predictive models and/or research tools and assays aimed at gaining a better understanding of the rules and compound properties governing the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens.

    Responsive projects must focus on one or more of the following Gram-negative bacterial pathogens: carbapenem-resistant Enterobacteriaceae (CRE), MDR Acinetobacter and/or MDR Pseudomonas aeruginosa. Projects must complete assay/tool/model development prior to the end of the third year of the project period and initiate discovery activities to demonstrate its utility in supporting a corresponding medicinal chemistry program to generate a lead chemical series with demonstrated activity against one or more targeted Gram-negative bacteria.

    This initiative will also support subsequent preclinical development of a promising lead antibacterial.

    Examples of assay and model development include, but are not limited to:

    • Quantitative cellular (or model system) assays to measure drug penetration and efflux, independent from standard MIC testing
    • Innovative quantitative assays to measure drug concentrations in bacterial cytoplasm and/or periplasmic space
    • Innovative technologies for assessment of the kinetics of drug penetration and efflux from bacteria
    • Computational algorithms for describing/predicting physical-chemical properties or guidelines needed by small molecules for optimal Gram-negative penetration and efflux avoidance.

    Successful projects will demonstrate the utility of the developed tools/assays to predict and measure potency of candidate therapeutics against Gram-negative targets. Preferably, this will be accomplished by using the developed models or assays to guide a medicinal chemistry campaign aimed at producing a novel chemical series with Gram-negative activity; or by screening existing libraries using the computational algorithms developed as a tool to find compounds with Gram-negative activity.

    Alternatively, the utility of the developed tools/assays can be demonstrated by profiling existing libraries of compounds with known Gram-negative activity.

    Further details are available via RFA-AI-16-081. The application deadline is May 18, 2017.

    Antimicrobials NIAID Request for Proposals
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – April 23, 2017
    Next Article Nonclinical Services for Development of Interventional Agents for Infectious Diseases

    Related Stories

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Black Death Impact on Microbiome May Have Contributed to Modern-Day Chronic Diseases

    November 29, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.